Arvinas (ARVN) vs DBV Technologies S.A. (DBVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Arvinas (ARVN) has outperformed DBV Technologies S.A. (DBVT) over the past year, losing 26.8% versus a loss of 46.6%. Over five years, DBVT leads with a -18.0% price change compared with -91.8% for ARVN. DBV Technologies S.A. is the larger company by market cap ($568.8 million vs $449.7 million), about 1.3 times the size.
Arvinas converts more of its revenue into profit, with a net margin of -30.8% versus -2607.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARVN | DBVT |
|---|---|---|
| Share price | $6.97 | $9.05 |
| Market cap | $449.71M | $568.78M |
| 1-day change | -2.65% | -0.66% |
| YTD return | -41.23% | -52.79% |
| 1-year return | -26.79% | -46.61% |
| 5-year return | -91.79% | -18.03% |
| P/E ratio (TTM) | 26.81 | — |
| EPS (TTM) | $0.26 | $-3.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $262.60M | $5.64M |
| Revenue growth (YoY) | -0.30% | +35.77% |
| Net income (latest FY) | $-80.80M | $-146.95M |
| Operating margin | -45.13% | -2609.23% |
| Net margin | -30.77% | -2607.29% |
| 52-week high | $14.51 | $26.19 |
| 52-week low | $6.74 | $8.63 |
| Distance from 52-week high | -51.96% | -65.44% |
| Analyst consensus | buy | none |
| Avg. price target upside | +99.86% | +328.07% |
| Average volume | 800.32K | 350.73K |
| Shares outstanding | 64.52M | 62.85M |
| Employees | 246 | 170 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARVN has outperformed DBVT by 19.8 percentage points over the past year.
- Arvinas is more profitable, keeping -30.8 cents of every revenue dollar as net income versus -2607.3 cents for DBV Technologies S.A..
- DBV Technologies S.A. grew revenue faster in its latest fiscal year (+35.77% vs -0.30%).
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Healthcare · Biotechnology · 246 employees
About DBV Technologies S.A.
DBVT stock →DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Healthcare · Biotechnology · 170 employees
ARVN vs DBVT FAQ
Which is bigger, Arvinas or DBV Technologies S.A.?
DBV Technologies S.A. (DBVT) is larger, with a market capitalization of $568.78M compared with $449.71M for Arvinas (ARVN).
Which stock has performed better over the past year, ARVN or DBVT?
ARVN returned -26.79% over the past 12 months, compared with -46.61% for DBVT (price return, excluding dividends). Past performance does not predict future results.
Are Arvinas and DBV Technologies S.A. in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.